The global chemoinformatics market size is expected to reach USD 9.41 billion by 2030, registering a CAGR of 15.5% during the forecast period, according to a new report by Grand View Research, Inc. Some major determinants influencing the market growth include the constantly improving modern drug development processes, increasing use of in-silico techniques in research, and the advantages associated with employing the chemoinformatics approach, such as the reduction in the overall R&D expenditure during the drug development process.
The ever increasing growth of the drug development market will boost the demand for chemoinformatics owing to its numerous applications in drug designing at various stages. Right from target identification to its development as a potential drug candidate, chemoinformatics tools play a crucial part.
The significant contributions of the varying in silico tools in the generation of hits through the High Throughput Screening(HTS) process, target compound selection, virtual structure generation, Pharmacokinetic property and toxicity prediction of chemical compounds, and the quantitative-structure relationship determination have been a major driving force for the growth of the chemoinformatics market.
The heavy costs incurred along with the long time span invested in the drug discovery process has made the integration of the chemoinformatics techniques essential in the research activities. It aids the scientists and chemical researchers in making better decisions pertaining to drug discovery and other related research studies. Furthermore, the increasing demand for efficient and effective medicines, rising investments in R&D, growing geriatric population, and the burgeoning number of individuals with lifestyle related diseases are expected to positively reinforce the market growth. The key applications of the chemoinformatics tools and softwares in drug designing and discovery has been its largest application and is expected to grow further with further advances in the drug discovery process.
Chemoinformatics has made marked contributions to the areas of chemical drug development and research. The growth of this field is driven by the continually generated raw data in screening operations and research studies. Chemoinformatics in silico tools aid in effective data management, which facilitate data retrieval and analysis thus providing large databases of accessible information to scientists involved in both, the drug development process and other research related studies.
The development of three dimensional chemical structure databases has been a significant achievement in the field of chemoinformatics as it has significantly aided the research process. Applications of chemoinformatics platforms in computer-assisted synthesis designing, computer-assisted structure elucidation, and chemometrics have further contributed to the market growth.
The advancements in computational technology have been a high impact rendering driver for the market growth. In this direction, the development of super computers and silicon graphics computer for calculations, 3D structure generation, molecular graphics, and complex data display have been pivotal in propelling the growth of the chemoinformatics market. With the advent of advanced WEB technologies and their incorporation in the in-silico computational techniques have totally revolutionized this field.
The increasing needs for advanced and efficient technologies to yield better results has made the chemoinformatics area an indispensable part of the pharmaceutical industry. The surging need for therapeutically-effective medicines coupled with the increasing investments in the R&D area and the advancements in computer technologies provide lucrative opportunities to the market for it to grow and flourish in the near future.
Request a free sample copy or view report summary: Chemoinformatics Market Report
The drug discovery segment is expected to witness a lucrative CAGR during the forecast period. The key factors contributing to the segment’s high growth include the increasing investments in R&D and the relatively low success rate of the potential leads as drug molecules.
In 2022, North America dominated the chemoinformatics market with a revenue share of over 43.6% on account of the following factors: the high investments pertaining to the R&D initiatives, technological advancements, the presence of major players in the drug manufacturing industry, and the increasing prevalence of lifestyle-related diseases. With respect to the global R&D spending, North America holds the largest share. Also, it holds a major share in the ADME-toxicology market that further spurs the growth of the chemoinformatics market.
Asia Pacific is identified as one of the fastest growing regional markets, growing at a lucrative CAGR of 20.3% during the forecast period. The growth of this market can be attributed to the growing research activities being conducted in economies, such as India, China, and Singapore. The key advantages associated with undertaking research activities in these countries include the low manufacturing and labor costs and the less stringent regulations, which attract many multinational players to the Asia Pacific region. Additionally, the government initiatives and funds that are deployed to improve the R&D infrastructure will further drive the market growth.
Grand View Research has segmented the global chemoinformatics market based on application, and region:
Chemoinformatics Application Outlook (Revenue, USD Million, 2018 - 2030)
Chemical Analysis
Drug Discovery
Drug Validation
Others
Chemoinformatics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Sweden
Norway
Denmark
Asia Pacific
China
Japan
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
Saudi Arabia
South Africa
UAE
Kuwait
BIOVIA (formerly Accelrys)
ACD/Labs, Inc.
Agilent Technologies, Inc.
Cambridgesoft Corp.
ChemAxon, Inc.
Bio-Rad Laboratories, Inc.
Schrödinger, LLC
Molecular Discovery Ltd.
"The quality of research they have done for us has been excellent..."